Study:
A Pilot (Phase I) Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor Risk Stage III Non-Small Cell Lung Cancer
Rationale:
Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some
find tumor cells and kill them or carry tumor-killing substances to them. Others interfere
with the ability of tumor cells to grow and spread. Radiation therapy uses high-energy
x-rays to kill tumor cells. Giving docetaxel and cetuximab together with radiation therapy
may kill more tumor cells.
Purpose:
This phase I trial is studying the side effects and best dose of docetaxel when
given together with cetuximab and radiation therapy in treating patients with stage III
non-small cell lung cancer.
Study Status: Terminated
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Lung Cancer |
Biological: cetuximab
Drug: docetaxel
Radiation: radiation therapy |
Phase 1 |
Verified by
Southwest Oncology Group
January, 2013
Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group
ClinicalTrials.gov identifier: NCT00288054
Study Type: Interventional
Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Yuhchyau Chen, MD, PhD., Principal Investigator
Kishan J. Pandya, MD., Principal Investigator
Derick H. Lau, MD., Principal Investigator
Karen Kelly, MD., Principal Investigator
Laurie E. Gaspar, MD, MBA., Principal Investigator